Future Directions for [18F]FDG PET in Central Nervous System Diseases.

[18F]FDG PET is entering a new phase shaped by changes in representation, validation, and clinical integration. Beyond regional interpretation, network-based and computational approaches aim to provide more explicit and individualized descriptions of brain dysfunction. At the same time, dynamic [18F]FDG PET and total-body PET expand the field toward temporal physiology and systemic brain-body interactions. The clinical impact of these advances will depend on standardized, reproducible, and scalable frameworks that support multicenter deployment and clinically meaningful interpretation. In this evolving biomarker ecosystem, [18F]FDG PET is well positioned to serve as a functional anchor.